Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Cancer Research and Clinical Oncology
Published in: Journal of Cancer Research and Clinical Oncology 5/2005

01-05-2005 | Letter to the Editors

Reply concerning “Clinical evaluation of in vitro chemosensitivity testing: the example of uveal melanoma” by Terheyden et al. (2004)

Authors: P. Terheyden, E.-B. Bröcker, J. C. Becker

Published in: Journal of Cancer Research and Clinical Oncology | Issue 5/2005

Login to get access

Excerpt

We are very grateful for the critical and valuable discussion of our paper by Ian Cree and colleagues, even if their letter partially lacks the appropriate style of scientific discussions. Cree et al. mainly judge our trial from the laboratory point of view, which is justified in some aspects, but does not necessarily reflect the clinical situation. It is actually surprising that Cree and colleagues became upset when we tested their suggestion that “treosulfan and gemcitabine might be more active than other drugs” and observed rather discouraging clinical efficacy. …
Literature
Avril MF, Aamdal S, Grob JJ, et al (2004) Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 22:1118–1125
Eskelin S, Pyrhönen S, Hahka-Kemppinen M, Tuomaala S (2003) A prognostic model and staging for metastatic uveal melanoma. Cancer 97:465–475CrossRefPubMed
Flaherty LE, Liu PY, Unger J, Sondak VK (1997) Comparison of patient characteristics and outcome between a single-institution phase II trial and a cooperative-group phase II trial with identical eligibility in metastatic melanoma. Am J Clin Oncol 20:600–604
Pföhler C, Cree IA, Ugurel S, Kuwert C, et al (2003) Treosulfan and gemcitabine in metastatic uveal melanoma patients: results of a multicenter feasibility study. Anticancer Drugs 14:337–340CrossRefPubMed
Serrone L, Zeuli M, Sega FM, Cognetti F (2000) Dacarbacine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res 19:21–34
Metadata
Title
Reply concerning “Clinical evaluation of in vitro chemosensitivity testing: the example of uveal melanoma” by Terheyden et al. (2004)
Authors
P. Terheyden
E.-B. Bröcker
J. C. Becker
Publication date
01-05-2005
Publisher
Springer-Verlag
Published in
Journal of Cancer Research and Clinical Oncology / Issue 5/2005
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-004-0631-2

Other articles of this Issue 5/2005

Journal of Cancer Research and Clinical Oncology 5/2005 Go to the issue

Original Paper

Oral capecitabine plus subcutaneous interferon alpha in advanced squamous cell carcinoma of the skin

Original Paper

Glucocorticoids induce G1 cell cycle arrest in human neoplastic thymic epithelial cells

Original Paper

Characterization of the combined cellular survival effects of benzoquinone-ansamycins and ionizing radiation

Original Paper

Expression of homeodomain protein CDX2 in gallbladder carcinomas

Original Paper

The prognostic factor for outcome following second resection for intrahepatic recurrence of hepatocellular carcinoma with a hepatitis B virus infection background

Original Paper

Combination treatment of CC531-lac-Z rat liver metastases by chemoembolization with pemetrexed disodium and gemcitabine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits